RUNX3 Antibody - #AF5188

(2)   (3)  
Product: RUNX3 Antibody
Catalog: AF5188
Description: Rabbit polyclonal antibody to RUNX3
Application: WB IHC IF/ICC
Reactivity: Human, Mouse
Prediction: Pig, Bovine, Horse, Rabbit, Dog, Xenopus
Mol.Wt.: 44 kDa; 44kD(Calculated).
Uniprot: Q13761
RRID: AB_2837674

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IF/ICC 1:100-1:500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse
Prediction:
Pig(100%), Bovine(100%), Horse(100%), Rabbit(100%), Dog(100%), Xenopus(80%)
Clonality:
Polyclonal
Specificity:
RUNX3 Antibody detects endogenous levels of total RUNX3.
RRID:
AB_2837674
Cite Format: Affinity Biosciences Cat# AF5188, RRID:AB_2837674.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

Acute myeloid leukemia 2 protein; Acute myeloid leukemia gene 2; AML 2; AML2; CBF alpha 3; CBF-alpha-3; CBFA 3; CBFA3; Core binding factor alpha 3 subunit; core binding factor; Core binding factor runt domain alpha subunit 3; Core binding factor subunit alpha 3; core-binding factor; Core-binding factor subunit alpha-3; Oncogene AML 2; Oncogene AML-2; PEA2 alpha C; PEA2-alpha C; PEBP2 alpha C; PEBP2-alpha C; Pebp2a3; PEBP2aC; Polyomavirus enhancer binding protein 2 alpha C subunit; Polyomavirus enhancer-binding protein 2 alpha C subunit; runt domain alpha subunit 3; runt related transcription factor 3; Runt-related transcription factor 3; RUNX 3; Runx3; RUNX3_HUMAN; SL3 3 enhancer factor 1 alpha C subunit; SL3-3 enhancer factor 1 alpha C subunit; SL3/AKV core binding factor alpha C subunit; SL3/AKV core-binding factor alpha C subunit; Transcription factor AML2;

Immunogens

Immunogen:
Uniprot:

Q13761(RUNX3_HUMAN) >>Visit HPA database.

Gene(ID):
RUNX3(864)
Expression:
Q13761 RUNX3_HUMAN:

Expressed in gastric cancer tissues (at protein level).

Description:
CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, lck, IL-3 and GM-CSF promoters.
Sequence:
MRIPVDPSTSRRFTPPSPAFPCGGGGGKMGENSGALSAQAAVGPGGRARPEVRSMVDVLADHAGELVRTDSPNFLCSVLPSHWRCNKTLPVAFKVVALGDVPDGTVVTVMAGNDENYSAELRNASAVMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPTQVATYHRAIKVTVDGPREPRRHRQKLEDQTKPFPDRFGDLERLRMRVTPSTPSPRGSLSTTSHFSSQPQTPIQGTSELNPFSDPRQFDRSFPTLPTLTESRFPDPRMHYPGAMSAAFPYSATPSGTSISSLSVAGMPATSRFHHTYLPPPYPGAPQNQSGPFQANPSPYHLYYGTSSGSYQFSMVAGSSSGGDRSPTRMLASCTSSAASVAAGNLMNPSLGGQSDGVEADGSHSNSPTALSTPGRMDEAVWRPY

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Dog
100
Rabbit
100
Xenopus
80
Sheep
0
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q13761 As Substrate

Site PTM Type Enzyme
T14 Phosphorylation
S17 Phosphorylation
K94 Acetylation
K94 Ubiquitination
K129 Ubiquitination
K148 Ubiquitination
S149 Phosphorylation P11309 (PIM1)
T151 Phosphorylation P11309 (PIM1)
T153 Phosphorylation P11309 (PIM1)
T155 Phosphorylation P11309 (PIM1)
K171 Acetylation
T173 Phosphorylation
K186 Ubiquitination
K192 Acetylation
K192 Sumoylation
K192 Ubiquitination
T209 Phosphorylation
S211 Phosphorylation
T212 Phosphorylation
S214 Phosphorylation
R216 Methylation
S220 Phosphorylation
T222 Phosphorylation
S227 Phosphorylation
T231 Phosphorylation
S243 Phosphorylation
S251 Phosphorylation
T254 Phosphorylation
S261 Phosphorylation
R262 Methylation
R267 Methylation
R302 Methylation
S356 Phosphorylation P11802 (CDK4)

Research Backgrounds

Function:

Forms the heterodimeric complex core-binding factor (CBF) with CBFB. RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The heterodimers bind to the core site of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF promoters (By similarity). May be involved in the control of cellular proliferation and/or differentiation. In association with ZFHX3, upregulates CDKN1A promoter activity following TGF-beta stimulation. CBF complexes repress ZBTB7B transcription factor during cytotoxic (CD8+) T cell development. They bind to RUNX-binding sequence within the ZBTB7B locus acting as transcriptional silencer and allowing for cytotoxic T cell differentiation. CBF complexes binding to the transcriptional silencer is essential for recruitment of nuclear protein complexes that catalyze epigenetic modifications to establish epigenetic ZBTB7B silencing (By similarity).

PTMs:

Phosphorylated on tyrosine residues by SRC. Phosphorylated by LCK and FYN.

Subcellular Location:

Nucleus. Cytoplasm.
Note: The tyrosine phosphorylated form localizes to the cytoplasm. Translocates from the cytoplasm to the nucleus following TGF-beta stimulation.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in gastric cancer tissues (at protein level).

Subunit Structure:

Heterodimer with CBFB. RUNX3 binds DNA as a monomer and through the Runt domain. DNA-binding is increased by heterodimerization (By similarity). Interacts with TLE1 and SUV39H1and. The tyrosine phosphorylated form (via runt domain) interacts with SRC (via protein kinase domain). Interacts with FYN and LCK. Interacts with FOXP3. Interacts with ZFHX3. Interacts with TBX21 (By similarity).

Family&Domains:

A proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes.

Research Fields

· Organismal Systems > Immune system > Th1 and Th2 cell differentiation.   (View pathway)

References

1). MiR-93-5p promotes gastric cancer-cell progression via inactivation of the Hippo signaling pathway. GENE, 2018 (PubMed: 29045821) [IF=3.5]

Application: WB    Species: human    Sample:

Figure 4. FAT4 and LATS2 are direct miR-93-5p targets. (A) Quantitative PCR results showed that miR-93-5p overexpression suppressed FAT4 and LATS2 mRNA expression in SGC-7901 cells, while conversely, the opposite result was observed in HGC-27 cells exhibiting downregulated miR-93-5p expression. RUNX3 and RASSF2 mRNA levels were unchanged in response to either up- or downregulation of miR-93-5p. (B) Western blot analyses of FAT4, LATS2, RUNX3, and RASSF2 expression after transfection with miR-93-5p mimics and/or the miR-93-5p inhibitor.
2). Regulation of RUNX3 Expression by DNA Methylation in Prostate Cancer [Retraction]. Cancer Management and Research, 2021 (PubMed: 35002319) [IF=3.3]

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.